Lallemand Pharma

Новости подробнее

Сен
25,
2018

Benefits of PMBL® in asthmatic population: results of EOLIA study and pharmaco-economic adding value

Сен 25, 2018

Pr Emeryk (Pulmonologist, Allergist and Pediatrician University Children Hospital of Lublin, Poland) has been lately questioned about the benefits of bacterial lysates in asthmatic population: results of EOLIA study and pharmaco-economic adding value.

Discover the detailed interview:

Question 1 : Why did you study the benefits of bacterial lysates in asthmatic population?

Pr Emeryk : “Asthma is still a poorly controlled disease in children and adults. Asthma exacerbations associated with respiratory tract infections are a significant medical problem. New therapeutic options are being thought to improve the clinical course of asthma in children.”

Question 2 : What is the most important result and adding value of PMBL sublingual tablets in EOLIA study?

Pr Emeryk : “PMBL® Tablet (Ismigen®) reduces the number of asthma exacerbations in school-age children with IgE-dependent asthma. Treatment with PMBL® Tablet prolonged the time to second asthma exacerbation by 55% and to third asthma exacerbation by 74%. These therapy also reduces SABA (Short Acting Beta Agonists) consumption.”

Question 3 : As regard to Pharmaco-economic data, what were the most relevant results?

Pr Emeryk : “Treatment with PMBL® Tablet allows cost-saving and provides better control of the disease in comparison to the placebo group. The largest reduction in costs was observed from the perspective of a patient (10 euros per month) and of the society (17 euros per month).